- Poster presentation
- Open Access
Antibiotics’ consumption to early detect epidemics of P. aeruginosa in a burn center: a paradigm shift in the epidemiological surveillance of nosocomial infections
© Fournier et al; licensee BioMed Central Ltd. 2015
- Published: 16 June 2015
- Candida Albicans
- Nosocomial Infection
- Paradigm Shift
- Epidemiological Surveillance
- Consumption Survey
The control of antibiotic resistance and nosocomial infections are among the major challenges for specialized burn centers. Early detection of those epidemic outbreaks is crucial to limit the human and financial burden.
We hypothesize that data collected in the frame of antibiotic consumption medico-economic surveys could be used as warning signal to detect early nosocomial outbreaks.
Retrospective analysis including all burn patients staying more than 48 h and receiving systemic therapeutic antibiotics admitted to the Lausanne BICU between January 2001 and October 2012. Infection episodes were characterized according to predefined criteria. Antibiotic consumption data, obtained from the quarterly surveillance of drug consumption surveys, were translated in defined daily doses (DDDs).
297 out of 414 burn patients stayed more than 48 h for a total number of 7458 burn-days. We identified 610 infection episodes (burn wound [32.0%], respiratory [31.1%], catheter [21.8%]), due to 774 microorganisms. Pseudomonas aeruginosa (26.2%), Staphylococcus aureus (11.5%), Candida albicans (7.0%) were the main pathogens. We observed three distinct outbreaks of P. aeruginosa infections (2002-2003, 2006 and 2009-2011). These outbreaks were correlated with an increase in the DDD of anti-Pseudomonas antibiotics.
Our data support a paradigm shift in the epidemiological surveillance of nosocomial P. aeruginosa epidemics in Burn Centers, by using the rise in antibiotic consumption as an early trigger to initiate molecular typing of P. aeruginosa strains and reinforcement of standard infection control procedures.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.